Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Accuray (ARAY) Reports Loss In Q4, Revenues Beat Estimates

Published 08/15/2019, 09:47 PM
Updated 07/09/2023, 06:31 AM
US500
-
ISRG
-
BAX
-
SYK
-
ARAY
-

Accuray Incorporated (NASDAQ:ARAY) reported fourth-quarter fiscal 2019 adjusted loss of 2 cents per share against the Zacks Consensus Estimate of earnings per share (EPS) of 3 cents. The company had reported a loss of a penny in the year-ago quarter.

Net revenues of the Zacks Rank #3 (Hold) company totaled $117.4 million, surpassing the Zacks Consensus Estimate by 1.1%. On a year-over-year basis, revenues climbed 3.2%.

FY19 at a Glance

For fiscal 2019, revenues totaled $418.8 million, beating the Zacks Consensus Estimate of $417.5 million and increasing 3.4% year over year.

Adjusted net loss for fiscal 2019 was 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 16 cents. The year-ago figure was a loss of 28 cents.

Accuray reports through two major segments — Product and Service.

For the fiscal year, Product revenues were $196.7 million (47% of net sales), up 6.9% year over year. Service revenues were $222.1 million (53%), up 0.5%.

Fiscal Q4 Details

Product Revenues: Product revenues increased 11% year over year to $60.6 million in the reported quarter on strong demand for the Radixact system.

Service Revenues: Service revenues totaled $56.8 million, down 4% from the year-ago quarter.

Gross Order Update: Gross orders in the fiscal fourth quarter totaled $97.2 million, up 0.8% year over year. The upside was driven by strong demand for Radixact, CyberKnife and TomoTherapy platforms. Radixact accounted for approximately 60% of total gross orders while CyberKnife grew double digits.

U.S. gross orders declined in the reported quarter while that in EMEA grew mid-single digits.

Accuray Incorporated Price, Consensus and EPS Surprise

Accuray Incorporated Price, Consensus and EPS Surprise

Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote

Margins

Gross profit in the fiscal fourth quarter totaled $45.9 million, down 4.3% on a year-over-year basis. Gross margin was 39.1%, highlighting a contraction of 310 basis points (bps) year over year.

Research and development expenses rose 10% year over year to $16.1 million. Selling and marketing expenses declined 11.5% to $14.9 million. General and administrative expenses contracted 13% to $11.7 million.

Fourth-quarter operating profit was $3.3 million, up 5.3% from the year-ago quarter. Operating margin was 2.8%, up 10 bps year over year.

Cash Position

The company exited fourth-quarter fiscal 2019 with total cash, cash equivalents, and short-term restricted cash of $87 million, compared with $22.4 million at the end of Mar 31, 2019.

FY20 Guidance

For fiscal 2020, Accuray expects revenues within $410-$420 million. The Zacks Consensus Estimate for the same is pegged at $434.1 million, much higher than the projected range. Per management, Accuray has slashed its guidance by 1.5%. The company expects revenues from EMEA and Japan to remain flat or slightly below the fiscal 2019 levels. In the United States, Accuray expects modest revenue growth in fiscal 2020.

Our Take

Accuray wrapped up the fiscal fourth quarter on a mixed note. However, solid demand for the company’s Radixact, CyberKnife and TomoTherapy platforms has continued to boost business. We are also upbeat to note that this was the company’s fifth consecutive quarter of double-digit growth in gross orders, which was driven by continued strength in China. Accuray has also significantly operationalized its China joint venture agreement, which was signed earlier this year. A promising pipeline is expected to broaden the company’s product portfolio in the near term.

On the flip side, declining gross orders in United States raise concern. Gross margin significantly contracted in the quarter. Additionally, Accuray’s Service revenues were soft in the fiscal fourth quarter. A dull guidance for fiscal 2020 adds to the woes.

Earnings of Other MedTech Majors at a Glance

Some better-ranked stocks which posted solid results this earning season are Stryker Corporation (NYSE:SYK) , Baxter International Inc. (NYSE:BAX) and Intuitive Surgical, Inc. (NASDAQ:ISRG) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%.

Baxter delivered second-quarter 2019 adjusted EPS of 89 cents , which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%.

Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Revenues were $1.1 billion, surpassing the Zacks Consensus Estimate of $1.03 billion.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Accuray Incorporated (ARAY): Free Stock Analysis Report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Baxter International Inc. (BAX): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.